Shanghai-based MicroPort Scientific Corp. (HKG: 0853) has announced that its France-based subsidiary, MicroPort Cardiac Rhythm Management Limited (MicroPort CRM), has received market approvals for its ULYS implantable cardioverter defibrillators (ICDs) and INVICTA defibrillation electrode leads in Japan. This milestone marks a significant expansion for MicroPort in the Japanese medical device market.
Innovative Technology in ULYS ICDs
The ULYS ICD is designed with advanced technology that emphasizes low power consumption and boasts the longest expected service life among current ICD products, projected to last up to eight years. It incorporates the PARAD+ arrhythmia discrimination algorithm, clinically validated to achieve the lowest rate of inappropriate shock defibrillation. Additionally, the ULYS device features an AutoMRI function, allowing it to automatically switch to a specific mode during MRI examinations to ensure patient safety.
INVICTA Leads Enhance Cardiac Care
MicroPort’s INVICTA defibrillation lead continuously transmits electrocardiogram signals from the right ventricle to the defibrillator. In cases of bradycardia or life-threatening ventricular arrhythmias, it works in conjunction with the defibrillator to deliver pacing pulses or shock defibrillation signals as needed. The safety and efficacy of the INVICTA lead have been validated through the Apollo clinical research project, which reported a 100% implantation success rate and a 97.4% complication-free rate at the primary clinical endpoint of three months.
Conclusion: Strengthening MicroPort’s Position in Cardiac Care
The approval of ULYS ICDs and INVICTA leads in Japan is a testament to MicroPort’s commitment to advancing cardiac care technology. With these innovative products, MicroPort CRM is well-positioned to enhance patient outcomes and expand its footprint in the competitive medical device landscape.-Fineline Info & Tech
